Dr. Muthusamy Velusamy, MD
What this data tells you about Dr. Velusamy
Dr. Muthusamy Velusamy is a cardiovascular disease in Tampa, FL, with 20 years in practice. Based on federal Medicare data, Dr. Velusamy performed 7,561 Medicare services across 3,030 unique beneficiaries.
Between the years covered by Open Payments, Dr. Velusamy received a total of $31,298 from 49 pharmaceutical and/or device companies across 311 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Velusamy is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 3,279 | $0 | $2 |
| EKG interpretation and report | 1,573 | $6 | $20 |
| Office visit, established patient (30-39 min) | 751 | $98 | $250 |
| Electrocardiogram (EKG), 12-lead | 266 | $11 | $40 |
| Hospital follow-up visit, moderate complexity | 172 | $62 | $180 |
| Echocardiogram, transthoracic | 170 | $147 | $500 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 154 | $174 | $220 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 137 | $91 | $275 |
| Injection of chemical agent into single incompetent vein of leg using ultrasound guidance | 134 | $1,014 | $3,000 |
| Initial hospital admission, high complexity | 134 | $137 | $500 |
| Office visit, established patient, complex (40-54 min) | 122 | $138 | $348 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 93 | $144 | $475 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 83 | $328 | $1,139 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 82 | $48 | $185 |
| Ultrasound of both sides of head and neck blood flow | 79 | $148 | $500 |
| New patient office visit (45-59 min) | 64 | $131 | $400 |
| Hospital follow-up visit, high complexity | 50 | $91 | $260 |
| Complete ultrasound of aorta, vena cava, groin vessels or bypass grafts | 35 | $138 | $475 |
| Programming of dual lead pacemaker system | 34 | $61 | $150 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 28 | $10 | $50 |
| Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring, transmission and review and report by health care professional | 23 | $18 | $65 |
| Initial hospital admission, moderate complexity | 23 | $106 | $350 |
| Cardiac catheterization | 21 | $176 | $830 |
| Ultrasound of leg arteries or artery grafts | 21 | $186 | $625 |
| New patient office visit, complex (60-74 min) | 19 | $176 | $500 |
| Ultrasonic guidance for blood vessel access | 14 | $11 | $35 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (50%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
5.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Velusamy is a mixed practice specialist, with above-average Medicare volume (top 12% in FL), and high industry engagement (mixed engagement, top 11%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Velusamy experienced with injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)?
Does Dr. Velusamy receive payments from pharmaceutical companies?
How do Dr. Velusamy's costs compare to other cardiovascular diseases in Tampa?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology